

Opening

Carlos Correa
Executive Director
South Centre

Patent AR017747B1 -Bristol Myers Squibb

DIDANOSINE pharmaceutical composition: pharmaceutical capsules with enteric coating, optionally coated with non-stick agent arranged on the outside of said enteric coating.

Bristol Myers Squibb

- Through Bristol's decade-long pattern of alleged anticompetitive acts, Bristol avoided competition by abusing federal regulations in order to block generic entry; deceived the U.S. Patent and Trademark Office (PTO) to obtain unwarranted patent protection; paid a would-be generic rival over \$70 million not to bring any competing products to market; and filed baseless patent infringement lawsuits to deter entry by generics US Federal Trade Commission, 2003

<http://www.ftc.gov/opa/2003/03/bms.htm>



Guidelines for the examination of pharmaceutical patents:

Developing a public health perspective.

By Carlos Correa
University of Buenos Aires